• Overview & Objectives
  • Credit Eligibility
  • Funding Support
Date
Options: Nov 26, Dec 2 or 3, 2024
Time
View details and options
Credits
N/A
Details
Virtual (free)
View Agenda
Nov. 26, 2024 (6:00-7:00 pm PST)
Dec. 2, 2024 (7:00-8:00 pm AST)
Dec. 2, 2024 (7:30-8:30 pm EST)
Dec. 3, 2024 (7:00-8:00 pm EST)

Register

To register, please click your preferred date/time from the options above. 

Description

ATTR cardiomyopathy is an underdiagnosed condition with high morbidity and mortality. With new disease-modifying treatments available, the prognosis for patients with ATTR cardiomyopathy can be substantially improved. This program will guide cardiologists in how to suspect and confirm diagnosis, which heart failure therapies to avoid using, and how to initiate disease-modifying therapies and obtain drug reimbursement. 

Target Audience 

Cardiologists and Internists

Learning Objectives 

Following participation in this program, participants will be able to:

  • Review a practical diagnostic approach to ATTR-cardiomyopathy 
  • Discuss which heart failure therapies to use and to avoid 
  • Facilitate obtaining coverage and initiating disease-modifying treatments 

Faculty

Margot Davis, MD, MSc, FRCPC, FCCS

Ryan Davey, MD, FRCPC, FACC

Moderator

Milan Gupta, MD, FRCPC, FCCS, CPC(HC)